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treatment outcomes of ceftriaxone-resistant Salmonella will
be discussed.
doi:10.1016/j.ijid.2008.05.145
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Fluroquinolone-resistant Gonorrhea
P.R. Hsueh
National Taiwan University Hospital, Taipei, Taiwan
The rapid emergence of ﬂuoroquinolone resistance among
Neisseria gonorrhoeae isolates with a preexisting high preva-
lence of penicillin resistance in the past decade is of
great concern. The prevalence of gonococcal resistance to
ciproﬂoxacin has increased rapidly worldwide in the past
few years, but this increase has varied considerably by
country, ranging from 2.1% in Canada to 86.9% in China.
In Taiwan, ciproﬂoxacin-resistant N. gonorrhoeae was ﬁrst
isolated in 1998. A remarkable increase in the preva-
lence of ciproﬂoxacin resistance was found between 2001
(66.7%) and 2003 (95.2%) at National Taiwan University
Hospital. Previously established guidelines for the manage-
ment of gonorrhea in adults in the United States and the
United Kingdom recommended the use of a ﬂuoroquinolone
(e.g., oﬂoxacin, ciproﬂoxacin, or levoﬂoxacin) as a ﬁrst-
line option for gonorrhea therapy. Failure of gonococcal
infections caused by N. gonorrhoeae strains with resis-
tance to ciproﬂoxacin to respond to treatment with these
agents has been well documented. Accordingly, a ﬂuoro-
quinolone is no longer a ﬁrst-line option for the treatment
of gonorrhea in many countries, particularly those with
high incidence of ﬂuoroquinolone resistance in gonococcal
isolates. Spectinomycin and a cephalosporin (e.g., cefpo-
doxime or ceftriaxone) might be used as the ﬁrst-line agent
for the treatment of gonorrhea, although some gonococcal
isolates exhibiting resistance to the above agents have been
reported.
doi:10.1016/j.ijid.2008.05.146
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Antimicrobial Resistance Among Anaerobes -The
European Experience
C.E. Nord
Karolinska Institute, Karolinska University Hospital,
Stockholm, Sweden
Clinical usage of antimicrobial agents has been accompanied
by the isolation of antimicrobial-resistant bacteria. During
the last years there have been reports showing increas-
ing numbers of anaerobic bacteria resistant to different
antimicrobial agents in Europe. Resistance in anaerobic
bacteria has a signiﬁcant impact on the selection of antimi-
crobial agents for empirical therapy. The development of
antibiotic resistance in anaerobic bacteria has been doc-
umented for beta-lactam drugs, clindamycin, macrolides,
tetracyclines, ﬂuoroquinolones and nitroimidazoles. The
Bacteroides fragilis group is more resistant to antimi-
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robial agents than most other anaerobic bacteria. The
acteroides genus and the genera Prevotella and Por-
hyromonas have become increasingly resistant to many
nti-anaerobic agents. Fusobacterium strains resistant to
eta-lactam drugs are relatively frequent. Resistant anaer-
bic cocci and Propionibacterium acnes have also been
eported. Recently, ﬂuoroquinolone-resistant Clostridium
ifﬁcile strains producing three toxins (toxin A, toxin B and
inary toxin) have been isolated from patients with severe
. difﬁcile diseases.
The resistance mechanisms in anaerobic bacteria are:
) hydrolysis of the antimicrobial drug by several enzymes
efore reaching the site of action (most common, some-
imes plasmid mediated); b) decreased permeability of the
rganisms; c) modiﬁcation at the site of action of the antimi-
robial agent; d) efﬂux mechanisms which eliminate the
ntimicrobial drug from the bacterial cell.
oi:10.1016/j.ijid.2008.05.147
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lostridium difﬁcile (CD) is an anaerobic bacterium capa-
le of forming spores which confer resistance to heating,
rying and chemical agents, including disinfectants. Spores
f CD may survive in the environment for long periods and
re resistant to alcohol. More than 150 PCR ribotypes and 24
oxinotypes have been recognized; epidemic ribotypes may
ave enhanced sporulation. Since 2003, increasing rates of
D infections (CDI) have been reported in North America
nd Europe involving a more severe course, higher mortal-
ty, increased risk of relapse and more complications. The
utbreaks are difﬁcult to control and require a multifaceted
pproach. The most important infection control measures
ct on interruption of transmission of spores to vulnerable
atients from infected patients and from the environ-
ent. Vulnerable patients are mainly patients who receive
ntimicrobial treatment, and therefore fewer antibiotic
rescriptions should lead to less vulnerable patients. At
resent, no sufﬁcient evidence exists to propagate the
se of probiotics to vulnerable patients for prevention
f CDI. Transmission of spores occurs mainly via contact
f contaminated health care workers to patients, directly
y patient-to-patient transmission or by transmission from
he contaminated environment to patients. There is no
irect evidence that patients or healthcare workers who are
ymptom-free but colonised with C. difﬁcile in the intestinal
ract are signiﬁcant sources of infection. Early diagnosis of
DI, prompt isolation of symptomatic patients and reduc-
ng antimicrobial treatment are essential ﬁrst steps. The
nfection control measures include recommendations to iso-
ate infected patient on a single room with designated
oilet, to apply proper hand hygiene with soap and water,
